This peptide has demonstrated protective effects in preclinical models of heart failure, neurodegenerative disease, and agerelated muscle atrophy, and received FDA accelerated approval in 2025 as the first treatment for Barth syndrome [3]
The commenter requested that CMS consider creating a Level 6 Neurostimulator APC that includes CPT code 64568, reassigning 64568 to New Technology APC 1580 (New TechnologyLevel 43 ($40,001-$50,000)) or creating a C-code through the pending New Technology APC application and assigning the C-code to New Technology APC 1581 (New TechnologyLevel 44 ($50,001-$60,000))
Teach coping strategies for sensory or social challenges
That is a meaningful shift for the clinical compounding ecosystem but it is not the same as FDA approval of a finished drug product
Some people report nothing
A patient with insufficiency needs a maintenance dose